Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Growth factors help regrow jawbone in small study

NCT ID NCT07654218

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This study tested a procedure that uses a patient's own growth factors to help rebuild lost jawbone. Eleven people with severe bone loss in the upper jaw received a bone graft mixed with plasma rich in growth factors. After 6-9 months, enough bone had grown to place dental implants. The results suggest this technique may be a safe way to prepare the jaw for implants, but larger studies are needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Plasma rich in growth factors (PRGF) combined with bone graft (autogenous bone and bovine bone mineral)
What this could lead to
If successful, this approach could provide a reliable way to rebuild jawbone in people with severe bone loss, allowing them to get dental implants and improve chewing and appearance.
What could go wrong
This was a very small study (11 people) with no comparison group, so results may not apply to everyone. The procedure is invasive and carries risks like infection, graft failure, or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

11 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Fully edentulous maxilla requiring implant-supported fixed oral rehabilitation * Atrophic maxillary alveolar ridge requiring vertical and/or horizontal bone augmentation before implant placement * Residual alveolar ridge width below 6 mm and/or residual bone height below 10 mm, as assessed by cone-beam computed tomography * ASA physical status I or II * Clinical indication for guided bone regeneration, with or without simultaneous maxillary sinus floor elevation * Adequate oral hygiene and willingness to comply with postoperative instructions and follow-up visits * Written informed consent provided. Exclusion Criteria: * ASA physical status III or higher * Uncontrolled systemic disease contraindicating oral surgery or bone regenerative procedures * Uncontrolled diabetes mellitus or other systemic condition expected to impair wound healing or bone regeneration * History of radiotherapy to the head and neck region * Current or previous intravenous antiresorptive or antiangiogenic therapy associated with risk of medication-related osteonecrosis of the jaw * Active oral infection at the surgical site * Untreated periodontal disease or poor oral hygiene incompatible with regenerative surgery * Heavy smoking or unwillingness to comply with perioperative smoking restrictions * Pregnancy or breastfeeding * Inability to understand the study procedures or provide informed consent * Inability or unwillingness to attend scheduled follow-up visits * Any medical, anatomical, or behavioural condition judged by the investigator to interfere with surgery, healing, follow-up, or interpretation of outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar bone loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alveolar Bone Loss Atrophic Maxilla periodontal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Faculty of Dental Medicine, University of Porto

    Porto, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.